Wiki-MPM
About
Search
Browse
People
Funding
Updates
Search
MAP2K1 and MAP3K4
Data Source:
BioGRID
(enzymatic study)
HPRD
(in vitro, in vivo)
MAP2K1
MAP3K4
Description
mitogen-activated protein kinase kinase 1
mitogen-activated protein kinase kinase kinase 4
Image
No pdb structure
GO Annotations
Cellular Component
Nucleus
Mitochondrion
Early Endosome
Late Endosome
Endoplasmic Reticulum
Golgi Apparatus
Microtubule Organizing Center
Cytosol
Plasma Membrane
Focal Adhesion
Cytoplasm
Perinuclear Region Of Cytoplasm
Molecular Function
Protein Kinase Activity
Protein Serine/threonine Kinase Activity
MAP Kinase Kinase Activity
Protein Serine/threonine/tyrosine Kinase Activity
Protein Tyrosine Kinase Activity
MAP-kinase Scaffold Activity
Protein Binding
ATP Binding
Protein C-terminus Binding
Protein Serine/threonine Kinase Activator Activity
Protein N-terminus Binding
Scaffold Protein Binding
MAP Kinase Kinase Kinase Activity
Protein Binding
ATP Binding
Metal Ion Binding
Biological Process
MAPK Cascade
Activation Of MAPK Activity
Protein Phosphorylation
Chemotaxis
Cell Cycle Arrest
Signal Transduction
Heart Development
Negative Regulation Of Cell Population Proliferation
Positive Regulation Of Gene Expression
Negative Regulation Of Gene Expression
Peptidyl-threonine Phosphorylation
Peptidyl-tyrosine Phosphorylation
Cerebellar Cortex Formation
Neuron Differentiation
Keratinocyte Differentiation
Thyroid Gland Development
Regulation Of Stress-activated MAPK Cascade
Positive Regulation Of Transcription, DNA-templated
Thymus Development
Regulation Of Axon Regeneration
Cell Motility
Positive Regulation Of Axonogenesis
Bergmann Glial Cell Differentiation
Face Development
Trachea Formation
Epithelial Cell Proliferation Involved In Lung Morphogenesis
Placenta Blood Vessel Development
Labyrinthine Layer Development
ERK1 And ERK2 Cascade
Positive Regulation Of ERK1 And ERK2 Cascade
Positive Regulation Of Protein Serine/threonine Kinase Activity
Regulation Of Golgi Inheritance
Cellular Senescence
Positive Regulation Of Production Of MiRNAs Involved In Gene Silencing By MiRNA
Regulation Of Early Endosome To Late Endosome Transport
MAPK Cascade
Activation Of MAPKK Activity
Protein Phosphorylation
Response To UV-C
Positive Regulation Of Telomere Maintenance Via Telomerase
Intracellular Signal Transduction
Positive Regulation Of JUN Kinase Activity
Positive Regulation Of Telomerase Activity
Positive Regulation Of P38MAPK Cascade
Positive Regulation Of Telomere Capping
Pathways
MAPK3 (ERK1) activation
Frs2-mediated activation
Signal transduction by L1
Uptake and function of anthrax toxins
RAF activation
MAP2K and MAPK activation
Negative feedback regulation of MAPK pathway
MAP3K8 (TPL2)-dependent MAPK1/3 activation
Signaling by moderate kinase activity BRAF mutants
Signaling by high-kinase activity BRAF mutants
Signaling by BRAF and RAF fusions
Paradoxical activation of RAF signaling by kinase inactive BRAF
Signaling downstream of RAS mutants
Signaling by MAP2K mutants
Signaling by RAF1 mutants
Drugs
K-252a
5-Bromo-N-[(2S)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide
Cobimetinib
Bosutinib
(5S)-4,5-difluoro-6-[(2-fluoro-4-iodophenyl)imino]-N-(2-hydroxyethoxy)cyclohexa-1,3-diene-1-carboxamide
2-[(2-chloro-4-iodophenyl)amino]-N-{[(2R)-2,3-dihydroxypropyl]oxy}-3,4-difluorobenzamide
PD-0325901
N-(5-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl}-1,3,4-oxadiazol-2-yl)ethane-1,2-diamine
2-[(4-ETHYNYL-2-FLUOROPHENYL)AMINO]-3,4-DIFLUORO-N-(2-HYDROXYETHOXY)BENZAMIDE
Trametinib
Selumetinib
Fostamatinib
Diseases
Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
GWAS
Prostate cancer (
29892016
)
Testicular germ cell tumor (
28604728
28604732
)
Aging (
22773346
)
Blood protein levels (
28240269
)
Cognitive decline rate in late mild cognitive impairment (
26252872
)
Lipoprotein (a) levels (
26377243
)
Ovarian disease with few adhesions (
28333195
)
Interacting Genes
67 interacting genes:
APC
ARAF
AURKA
BANP
BAX
BIRC6
BMPR1A
BRAF
BUB1
CASP9
CDH1
CDK5
CDKN2A
CPNE1
CPNE4
CTNNA1
EGFR
ELK1
EP300
ERBB2
FBXW7
GRB10
HNRNPD
HRAS
KAT7
KSR1
KSR2
LAMTOR3
MAP3K4
MAP3K8
MAPK1
MAPK14
MAPK3
MAPK8
MAPK8IP3
MBP
MLH3
MSH6
MYC
ODC1
PAK1
PARVA
PDGFRL
PEBP1
PEBP4
PIK3CA
PLEKHF2
PLK3
PPARG
PRKCI
PRKCZ
PTPRJ
RAF1
RPS6KA2
RPS6KA4
SMAD2
SRC
STK11
TCP11
TGFBR2
TLR2
TRAF3
TRAF6
TRIB1
UBE2I
UBE2L3
WNK1
26 interacting genes:
ANXA2
AXIN1
BUB1B
CDC42
CHUK
CNTRL
DIXDC1
GADD45A
GADD45B
GADD45G
GSK3B
MAP2K1
MAP2K3
MAP2K4
MAP2K6
MAP2K7
MAPK13
MFHAS1
PTK2B
PTPN11
RAC1
RACGAP1
RUNX2
TPR
TRAF4
YWHAZ
Entrez ID
5604
4216
HPRD ID
01469
03886
Ensembl ID
ENSG00000169032
ENSG00000085511
Uniprot IDs
A4QPA9
B4DFY5
H3BRW9
Q02750
Q9P1M2
Q9Y6R4
PDB IDs
1S9J
2P55
3DV3
3DY7
3E8N
3EQB
3EQC
3EQD
3EQF
3EQG
3EQH
3EQI
3MBL
3ORN
3OS3
3PP1
3SLS
3V01
3V04
3VVH
3W8Q
3WIG
3ZLS
3ZLW
3ZLX
3ZLY
3ZM4
4AN2
4AN3
4AN9
4ANB
4ARK
4LMN
4MNE
4U7Z
4U80
4U81
5BX0
5EYM
5HZE
5YT3
6NYB
6PP9
6Q0J
6Q0T
6U2G
6X2P
6X2S
6X2X
Enriched GO Terms of Interacting Partners
?
Tagcloud
?
Tagcloud (Difference)
?
Tagcloud (Intersection)
?